Adequacy of pharmacological information provided in pharmaceutical drug advertisements in African medical journals

Main Article Content

Kazeem A. Oshikoya
Idowu O. Senbanjo
Ayo Soipe

Keywords

Advertisements, Periodicals as Topic, Nigeria, Africa

Abstract

Pharmaceutical advertisement of drugs is a means of advocating drug use and their selling but not a substitute for drug formulary to guide physicians in safe prescribing.

Objectives: To evaluate drug advertisements in Nigerian and other African medical journals for their adequacy of pharmacological information.

Methods: Twenty four issues from each of West African Journal of Medicine (WAJM), East African Medical Journal (EAMJ), South African Medical Journal (SAMJ), Nigerian Medical Practitioner (NMP), Nigerian Quarterly Journal of Hospital Medicine (NQJHM) and Nigerian Postgraduate Medical Journal (NPMJ) were reviewed. While EAMJ, SAMJ and NMP are published monthly, the WAJM, NQJHM and NPMJ are published quarterly. The monthly journals were reviewed between January 2005 and December 2006, and the quarterly journals between January 2001 and December 2006. The drug information with regards to brand/non-proprietary name, pharmacological data, clinical information, pharmaceutical information and legal aspects was evaluated as per World Health Organisation (WHO) criteria. Counts in all categories were collated for each advertiser.

Results: Forty one pharmaceutical companies made 192 advertisements. 112 (58.3%) of these advertisements were made in the African medical journals. Pfizer (20.3%) and Swipha (12.5%) topped the list of the advertising companies. Four (2.1%) adverts mentioned generic names only, 157 (81.8%) mentioned clinical indications. Adults and children dosage (39.6%), use in special situations such as pregnancy and renal or liver problems (36.5%), adverse effects (30.2%), average duration of treatment (26.0%), and potential for interaction with other drugs (18.7%) were less discussed. Pharmaceutical information such as available dosage forms and product and package information {summary of the generic and proprietary names, the formulation strength, active ingredient, route of administration, batch number, manufactured and expiry dates, and the manufacturer on both the container and pack of the drug} were mentioned in 65.6% and 50% adverts, respectively. The product and package descriptions were provided in 57 (72.2%) Nigerian medical journals, which was significantly higher than in other African medical journals 39 (37.9%) (P<0.001).

Conclusions: None of the drug advertisements in the journals adequately provided the basic information required by the WHO for appropriate prescribing. More guidance and regulation is needed to ensure adequate information is provided.

Downloads

Download data is not yet available.
Abstract 1190 | PDF Downloads 770

References

1. Bucci KK, Frey KA. Involvement of pharmacy faculty in the development of policies for pharmaceutical sales representatives. J Fam Pract. 1992;34:49-52.

2. Roy N, Madhiwalla N, Pai SA: Drug promotional practices in Mumbai: a qualitative study. Indian J Med Ethics. 2007;15:57-61.

3. Rohra DK, Gilani AH, Memon IK, Perven G, Khan MT, Zafar H, Kumar R. Critical evaluation of the claims made by pharmaceutical companies in drug promotional material in Pakistan. J Pharm Pharmaceut Sci. 2006;9:50-59.

4. Wazana A. Physicians and the pharmaceutical industry: is gift ever just a gift? JAMA. 2000;283:373-380.

5. Castresana L, Mejia RY, Aznar M. The attitude of physicians regarding the promotion strategies of the pharmaceutical industry. Medicina. 2005;65:247-251.

6. Wilkes MS, Doblin BH, Shapiro MF. Pharmaceutical advertisements in leading medical journals: Experts’ assessments. Ann Int Med. 1992;116:912-919.

7. Roughead EE. The pharmaceutical representative and medical practitioner encounter: implications for quality use of medicines. Masters Thesis: School of Health Systems Sciences, La Trobe University. August 1995

8. Bartus CL, Katz KA. Advertising in dermatology journals: journals’ and journal editors’ policies, practices, and attitudes. J Am Acad Dermatol. 2006;55:116-122.

9. Akande TM, Aderibigbe SA. Influence of drug promotion on prescribing habits of doctors in a teaching hospital. Afr J Med Med Sci. 2007;36:207-211.

10. Aders HP. Legal liability and drug prescribing. Curr Therap 1991;32:17-21.

11. Association of Medical Publishers: The value of medical journal advertising. Available at: http://www.ammonline.org/Media/Medical_Journal_Ad_Overview.pdf (Accessed October 10, 2007).

12. Paul CM, May EM. Seen by the doctor. Med Mark Media. 2004;39:44-51.

13. Accenture. Physicians seek more detailed, comparative and customized information from pharmaceutical reps. Accenture reserve funds. Available at: http://accenture.tekgroup.com/article_display.cfm?aerticle_id=4020 (Accessed on October 10, 2007).

14. Nies AS. Principles of therapeutics. In: Goodman and Gilman’s the pharmacological basis of therapeutics. Edited by Hardman JG, Limbird LE, Gilman AG. New York: Mc Graw-Hill; 2001, 64.

15. Rosenthal M, Berndt ER, Donohue JM, Frank RG, Epstein AM. Promotion of prescription drugs to consumers. N Engl J Med. 2002;346:498-505.

16. Tandon V, Gupta BM, Khajuria V. Pharmaceutical drug advertisements in national and international journals. Indian J Pharmacol. 2004;36:312-320.

17. World Health Organisation. Ethical criteria for medical drug promotion. Geneva: WHO 1988. ISBN 92-4-154239X Available at www.who.int/medicines/docs/criteriamedicinal.doc (Accessed March 30, 2001).

18. Scripture CD, Figg WD. Drug Interactions in Cancer Therapy. Nat Rev Cancer. 2006;6:546-558.

19. Kuhlmann J, Muck W. Clinical-pharmacological strategies to assess drug interaction potential during drug development. Drug Saf. 2001;24:715-725.

20. Oshikoya KA, Ojo OI. Medication errors in paediatric outpatient prescriptions in Nigeria. Niger Quart J Hosp Med. 2007;17:74-78.

21. Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook. 11th edition, Ohio: Lexi-Comp Inc.; 2004.

22. Ren XS, Kazis LE, Lee A, Zhang H, Miller DR. Identifying patient and physician characteristics that affect compliance with antihypertensive medications. J Clin Pharm Ther. 2002;27:47-56.

23. US Food and Drug Administration: Federal Food, Drug, and Cosmetic Act. Available at: http://www.access.gpo.gov/uscode/title21/chapter9_.html (updated 14 September 2005).

24. European Medicines Agency: EMEA/CHMP Working Group with Patients Organisations. Outcome of discussions: recommendations and proposal for action. London, 17 March 2005. Doc. Ref: EMEA/149479/2004 Final.

25. Vlassov V, Mansfield P, Lexchin J, Vlassova A. Do drug advertisements in Russian medical journals provide essential information for safe prescribing? West J Med. 2001;174:391-394.

26. National Drug Policy in South Africa: Department of Health (January 1996); 19.

27. Ransome Kuti O. National Drug Policy in Nigeria. J Pub Health Policy. 1992;13:367-373.

28. National Agency for Food and Drug Administration and Control. Drugs- general guidelines. Available at: http://www.nafdacnigeria.org/drugs.html (Accessed Dec 5, 2008).

29. The Division of Drug Marketing, Advertising, and Communication (DDMAC) of the U.S Food and Drug Administration (FDA). Information about the product we regulate. Available at: http://www.fda.gov/cder/drug/default.htm (Accessed Dec 5, 2008).

30. The World Association of Medical Editors: Impact Factor. Available at: www.wame.org/wame-listserve-discussions/impact-factor/ (Accessed March 12, 2004).

31. Home Journal Library Index: Impact Factor of Journals in the Order of Impact Factor. Available at: www.bioscience.org/services/impact 34.htm

32. International Network for the Availability of Scientific Publications. African Journal Online (AJOL): A Second Internal Evaluation, 2003-2005. Available at: http://www.inasp.info/uploaded/documents/AJOL-evaluation-2006-web1.pdf (Accessed June 5, 2006).

33. Pharmalot. FDA spanks Pfizer for schizophrenic drug advert. Available at: http://www.pharmalot.com/2007/08/fda-spanks-pfizer-for-schizo-drug-ad/ (Accessed Dec 5, 2008).

34. The age. Advert ban disappoints drug maker Roche. Available at: http://www.theage.com.au/news/Business/Ad-ban-disappoints-drug-maker-Roche/2007/08/30/1188067239979.html (Accessed Dec 5, 2008).

35. Medscape Medical News 2005. FDA reprimands Pfizer for Celebrex and Bextra adverts. Available at: http://www.medscape.com/viewarticle/538084 (Accessed Dec 5, 2008).

36. Oshikoya KA, Njokanma OF, Bello JA, Ayorinde EO. Family self medication for children in an urban area of Nigeria. Paediatr Perinat Drug Ther. 2007;8:124-130.

37. Oshikoya KA, Njokanma OF, Chukwura HA, Ojo OI. Adverse drug reactions in Nigerian Children. Paediatr Perinat Drug Ther. 2007;8:81-88.

38. Lexchin J, Kawachi I. The self-regulation of pharmaceutical marketing: initiatives for reform. In: Contested Ground: Public Purpose and Private Interest in the Regulation of Prescription Drugs. Ed: Davis P. New York: Oxford University Press;1996:221-235.

39. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behaviour of physicians. Am J Med. 1982;73:4-8.

Most read articles by the same author(s)